Form 4: Virios Therapeutics SVP of Finance, Angela Walsh, Acquires Stock Options
SEC Form 4
Angela Walsh, SVP of Finance at Virios Therapeutics, acquired stock options exercisable for 63,618 shares of common stock on February 26, 2024.
Summary
- On February 26, 2024, Angela Walsh, the SVP of Finance at Virios Therapeutics, acquired stock options.
- These options grant her the right to purchase 63,618 shares of Virios Therapeutics' common stock at an exercise price of $0.357 per share.
- The stock options will vest 100% on February 26, 2025, one year after the grant date.
- Following the transaction, Ms. Walsh directly owns 63,618 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, which is neither particularly positive nor negative. It reflects standard compensation practices.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of the stock option grant and transaction. |
| 02/26/2025 | Date the stock options vest 100%. |
| 02/26/2034 | Expiration date of the stock options. |
| 02/28/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, VIRI, Virios Therapeutics, insider trading, beneficial ownership, Angela Walsh
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.